Lantheus Holdings, Inc. (NASDAQ:LNTH) Receives Consensus Recommendation of “Hold” from Analysts

Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) have earned a consensus rating of “Hold” from the fourteen brokerages that are presently covering the company, MarketBeat Ratings reports. Ten analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 1-year target price among brokerages that have covered the stock in the last year is $108.1111.

A number of analysts have commented on the company. Brookline Capital Markets downgraded Lantheus from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 28th. Citizens Jmp restated a “market outperform” rating and set a $115.00 price objective on shares of Lantheus in a research report on Monday, June 29th. Mizuho cut their target price on Lantheus from $120.00 to $115.00 and set an “outperform” rating for the company in a research note on Wednesday, July 29th. Leerink Partners set a $102.50 target price on Lantheus in a research report on Monday, August 3rd. Finally, B. Riley Financial downgraded shares of Lantheus from a “buy” rating to a “hold” rating in a research note on Monday, August 17th.

Hedge Funds Weigh In On Lantheus

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. ABS Investment Management LLC bought a new stake in shares of Lantheus during the 2nd quarter valued at $232,974,000. Versant Capital Management Inc grew its holdings in shares of Lantheus by 33.0% during the 2nd quarter. Versant Capital Management Inc now owns 588 shares of the medical equipment provider’s stock worth $65,000 after purchasing an additional 146 shares in the last quarter. Abel Hall LLC increased its position in shares of Lantheus by 4.6% in the first quarter. Abel Hall LLC now owns 3,915 shares of the medical equipment provider’s stock worth $297,000 after purchasing an additional 172 shares during the period. Smartleaf Asset Management LLC increased its position in shares of Lantheus by 63.3% in the fourth quarter. Smartleaf Asset Management LLC now owns 508 shares of the medical equipment provider’s stock worth $34,000 after purchasing an additional 197 shares during the period. Finally, GAMMA Investing LLC raised its stake in Lantheus by 6.4% in the second quarter. GAMMA Investing LLC now owns 3,348 shares of the medical equipment provider’s stock valued at $371,000 after purchasing an additional 202 shares in the last quarter. 99.06% of the stock is owned by institutional investors.

Lantheus Stock Down 0.1%

Shares of LNTH opened at $100.25 on Friday. The company has a 50-day simple moving average of $102.18 and a 200-day simple moving average of $93.74. The firm has a market capitalization of $6.54 billion, a P/E ratio of 24.22 and a beta of -0.03. The company has a debt-to-equity ratio of 0.43, a quick ratio of 2.89 and a current ratio of 3.06. Lantheus has a 52 week low of $49.67 and a 52 week high of $111.86.

Lantheus (NASDAQ:LNTH) last released its earnings results on Thursday, August 6th. The medical equipment provider reported $1.55 earnings per share for the quarter, beating the consensus estimate of $1.30 by $0.25. Lantheus had a net margin of 17.69% and a return on equity of 28.10%. The business had revenue of $388.18 million during the quarter, compared to analysts’ expectations of $363.23 million. During the same quarter last year, the company earned $1.57 earnings per share. The firm’s revenue was up 2.7% on a year-over-year basis. On average, equities research analysts expect that Lantheus will post 4.5 earnings per share for the current year.

Lantheus Company Profile

Lantheus Holdings, Inc (NASDAQ: LNTH) is a healthcare company that develops, manufactures and commercializes diagnostic imaging agents and radiopharmaceuticals. Its products are designed to help physicians detect, characterize and monitor disease, with applications in cardiology, oncology and other areas of medicine.

The company’s principal products include DEFINITY, an ultrasound-enhancing agent used to improve cardiac ultrasound images, and PYLARIFY, a prostate-specific membrane antigen (PSMA) PET imaging agent used to help identify and assess prostate cancer.